Necitumumab
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | EGFR |
| Names | |
| Trade names | Portrazza |
| Clinical data | |
| Main uses | Squamous-cell cancer of the lung[1] |
| Side effects | Rash, low magnesium[2] |
| Routes of use | Intravenous infusion |
| Typical dose | 800 mg[2] |
| External links | |
| AHFS/Drugs.com | Monograph |
| US NLM | Necitumumab |
| Legal | |
| License data |
|
| Legal status |
|
| Pharmacokinetics | |
| Elimination half-life | ~14 days |
| Chemical and physical data | |
| Formula | C6436H9958N1702O2020S42 |
| Molar mass | 144844.87 g·mol−1 |
  (what is this?) (verify) | |
Necitumumab, sold under the brand name Portrazza, is a medication used for non-small-cell lung carcinoma (NSCLC).[1] Specifically it is used, together with gemcitabine and cisplatin, for squamous-cell cancer of the lung that has spread.[1] Such use; however, is not recommended in the United Kingdom.[3] It is given by gradual injection into a vein.[2]
Common side effects include rash and low magnesium.[2] Other side effects may include cardiac arrest and blood clots.[2] Use in pregnancy may harm the baby.[2] It is a monoclonal antibody that binds to epidermal growth factor receptor (EGFR).[3]
Necitumumab was approved for medical use in the United States in 2015.[1] While it was approved for use in Europe in 2016, this approval was subsequently withdrawn.[4] In the United Kingdom it cost the NHS £1,450 per dose as of 2021.[3] This amount in the United States costs about 4,500 USD.[5]
Medical uses
It was counterproductive in non-squamous non-small-cell lung carcinoma.[6][7]
Dosage
The typical dose is 800 mg on day 1 and 8 out of 21 days.[2]
References
- ↑ 1.0 1.1 1.2 1.3 "Necitumumab Monograph for Professionals". Drugs.com. Retrieved 12 November 2021.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "DailyMed - PORTRAZZA- necitumumab solution". dailymed.nlm.nih.gov. Retrieved 12 November 2021.
- ↑ 3.0 3.1 3.2 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 920. ISBN 978-0857114105.
- ↑ "Portrazza". Retrieved 12 November 2021.
- ↑ "Portrazza Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 12 November 2021.
- ↑ "Portrazza: Highlights of Prescribing Information" (PDF). www.accessdata.fda.gov. 2015. Retrieved 2019-09-28.
- ↑ Hand L (3 March 2015). "Necitumumab Fails in NSCLC". MedScape. Archived from the original on 2015-11-29. Retrieved 2015-11-25.
External links
| Identifiers: |
|
|---|
 | This monoclonal antibody–related article is a stub. You can help MDWiki by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help MDWiki by expanding it. |
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drug has EMA link
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Drugs that are a monoclonal antibody
- Articles with changed CASNo identifier
- Chemicals that do not have a ChemSpider ID assigned
- Articles with changed KEGG identifier
- Monoclonal antibodies for tumors
- Eli Lilly and Company brands
- All stub articles
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs